Brii Biosciences Ltd (FRA:7SS)

Full Year 2024 Brii Biosciences Ltd Earnings Call Transcript

Mar 31, 2025 / 12:30 PM GMT

Release Date Price: €0.28 (+2.94%)

Transcript

Key Points

Positve

Brii Biosciences Ltd (BRIBF) has made strategic decisions to prioritize R&D efforts, which has strengthened their cash position to support their mission of finding a cure for HPV.
The company presented promising data from their Ensure study, showing significant treatment effects of their assets, elapserin and BR179.
Brii Biosciences Ltd (BRIBF) has initiated multiple phase 2B combination studies, aiming to achieve higher functional cure rates for HPV across broader patient groups.
Their assets have been granted breakthrough therapy designation by the CDE in China, and fast track and breakthrough therapy designation by the FDA, indicating strong regulatory support.
The company has a strong cash position, with sufficient funds to support operations beyond 2028, allowing them to focus on late-stage development of their HPV programs.

Negative

Brii Biosciences Ltd (BRIBF) experienced a decrease in cash and cash equivalents by 9.3% compared to the previous year, primarily due to operational and R&D expenses.
Other income decreased by 13.6% due to lower bank interest income and reduced government grants.
The company had to reduce research and development expenses by 38% and administrative expenses by 22% due to pipeline prioritization and organizational optimization.
The competitive landscape for HPV treatments is evolving, requiring Brii Biosciences Ltd (BRIBF) to aim for higher functional cure rates, which may increase pressure on their R&D efforts.
There is uncertainty regarding the future inclusion of PEG interferon in HPV combination regimens, which could impact treatment strategies and outcomes.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

2137.HK - Brii Biosciences Ltd
Full Year 2024 Brii Biosciences Ltd Earnings Call
Mar 31, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good day everyone.

Thank you for standing by. Please be advised that today's call is being recorded. This call will be conducted in English. This is Kathy Yu, associate Director of Investor Relations. Welcome to Brei's 2024 annual results and corporate update conference call. Our annual results announcement can be found on the investor relations section of our company website.

Before we start, I would like to remind everyone that today's call may contain forward-looking statements, which involve several

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.